Outcome
| Type |
Measure |
Description |
Time frame |
Safety issue |
| Primary |
Changes of heart rate variability |
Nihon Kohden Electrocardiograph and Carepatch Electrocardiogram are used to measure heart rate variability, including standard deviation of all normal-to-normal R-R intervals (SDNN), standard deviation of sequential five-minute R-R interval means (SDANN), root-mean-square difference of successive normal R-R intervals (RMSSD), low frequency (LF), and high frequency (HF) in intervention and control groups. To eliminate possible errors, measurements are conducted by the same trained staff using the same instrument. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Primary |
Changes of forced expiratory volume in 1 s (FEV1) |
The pulmonary function measures are performed by the professional medical device. Before the pulmonary function test, subjects practice several times with the guidance of professional staff. During the examination, each subject in a sitting position and clamp the nose clip, and repeat the test, with the best result as the criterion. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Primary |
Changes of forced vital capacity (FVC) |
The pulmonary function measures are performed by the professional medical device. Before the pulmonary function test, subjects practice several times with the guidance of professional staff. During the examination, each subject in a sitting position and clamp the nose clip, and repeat the test, with the best result as the criterion. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Primary |
Changes of forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) ratio |
The pulmonary function measures are performed by the professional medical device. Before the pulmonary function test, subjects practice several times with the guidance of professional staff. During the examination, each subject in a sitting position and clamp the nose clip, and repeat the test, with the best result as the criterion. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Primary |
Changes of peak expiratory flow (PEF) |
The pulmonary function measures are performed by the professional medical device. Before the pulmonary function test, subjects practice several times with the guidance of professional staff. During the examination, each subject in a sitting position and clamp the nose clip, and repeat the test, with the best result as the criterion. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Primary |
Changes of fractional exhaled nitric oxide (FeNO) levels |
A NIOX VERO Sensor is used to measure fractional exhaled nitric oxide (FeNO) as a biomarker for airway inflammation. After deep breathing, the subjects gently inhaled into the device. The instrument shows FeNO level of the subjects. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Primary |
Changes of fractional exhaled carbon monoxide (FeCO) levels |
Use PICO to measure fractional exhaled carbon monoxide (FeCO) as a biomarker for cardiovascular risk. After deep breathing and holding the breath for 15 seconds, the subjects gently inhaled into the device. The instrument shows FeCO level of the subjects. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Primary |
Changes of blood pressure |
Using Omron blood pressure monitor to measure the systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure for each subject by the trained staff using the same instrument. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Secondary |
Changes of C-reactive protein (CRP) |
Detect the concentration of C-reactive protein (CRP) in blood sample to examine the different level of inflammation between the groups of intervention and control. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Secondary |
Changes of 8-hydroxydeoxyguanosine (8-OHdG) |
Detect the concentration of 8-hydroxydeoxyguanosine (8-OHdG) in urine sample of groups of intervention and control. 8-OHdG is a biomarker for DNA oxidative damage. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Secondary |
Changes of persistent response (PR) |
Examine persistent response (PR) as the index to test the focus ability of children. The test is performed by the Wisconsin Card Sorting Test (WCST) through a computer, and the index reflects the ability of cognitive transfer. The normal value is less than or equal to 27. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
| Secondary |
Differences in metabolite levels detected in metabolomics between groups of intervention and control. |
Mass spectrometry-based serum metabolomics is non-targeted. The study is to explore the differential metabolites in blood/urine/exhaled breath condensate (EBC) samples of the groups of intervention and control. |
Baseline and after the completion of intervention period (4 months anticipated) |
|
